MSK radiation oncologist Paul Romesser

Paul Romesser, MD

Radiation Oncologist & Early Drug Development Specialist

My Role at MSK

Areas of Expertise

My Specialties

  • Anal Cancer
  • Rectal Cancer
  • Metastases

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Share

About Me

What I Do at MSK
  • Director of Colorectal and Anal Cancer, Department of Radiation Oncology
Get To Know Me

Hello, I am Dr. Paul Romesser, a board-certified radiation oncologist specializing in the treatment of rectal and anal cancer. I understand that that facing these types of cancer can be overwhelming, but please know I am here to provide you and your family with compassionate care and unwavering support throughout your journey.

As the Director of Colorectal and Anal Cancer Radiation Oncology, my experience and leadership in this specialized field position me as a trusted authority in the treatment of these cancers. I am deeply committed to helping patients like you navigate the complexities of cancer care and work with you to create comprehensive treatment plans tailored to your specific needs and circumstances. Together, we will work towards the best possible outcome; your well-being is our top priority.

Read more

At Memorial Sloan Kettering Cancer Center, we believe in taking a collaborative and multidisciplinary approach (care involving experts across medical specialties) to cancer care. Working closely with surgical and medical oncologists, radiologists, and pathologists, I ensure that my patients receive the best care possible. I take great pride in the expertise of the team supporting my patients. I want my patients to feel assured that they are in the hands of a dedicated group of experts throughout their journey.

Patient education is of the utmost importance to me. I understand the significance of understanding your diagnosis and treatment options, and I will take the time to explain the role of radiation therapy in your overall treatment plan. My compassionate approach aims to address any concerns or questions you may have while empowering you with the knowledge needed to make informed decisions about your care.

In addition to my clinical practice, I am actively involved in groundbreaking research and clinical trials in cancer care. Sometimes, a new therapy or treatment method available in a clinical trial offers the best chance for cure. Patients who decide that a clinical trial is right for them have the opportunity to access cutting-edge treatments and contribute to the advancement of medical knowledge. I am passionate about pushing the boundaries of radiation oncology and believe that through research, we can uncover innovative solutions that will benefit patients like you.

Beyond my professional endeavors, I am driven by a genuine desire to make a positive impact on the lives of my patients and community. I volunteer on the board of the HPV Alliance and The Anal Cancer Foundation — two organizations dedicated to providing education and support for people with cancer. When I’m not working, I cherish the precious moments spent with my loving family and our dog, Easton.

I want you to feel reassured that when you visit my office, you are not just another patient, but someone who will receive personalized care and advocacy. Your journey towards healing is my top priority, and I am here to guide you every step of the way. With empathy, expertise, and unwavering support, I am dedicated to helping you work through the challenges of rectal and anal cancer while instilling hope and inspiring you to embrace the future with optimism. Together, we will conquer cancer and embark on a path to restored health and well-being.

My Role at MSK

A radiation oncologist is a cancer doctor with special training in using radiation therapy (RT) to treat cancer with radiation.

An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.

Areas of Expertise

My Specialties

  • Anal Cancer
  • Rectal Cancer
  • Metastases
  • Pancreas Cancer
  • Liver Cancer
  • Liver Metastases
  • Gastric Cancers
  • Endocrine Cancers
  • Small Bowel Cancers
  • Gallbladder & Bile Duct Cancers
Education & Honors

Education

  • MD, Boston University School of Medicine

Residencies

  • Radiation Oncology - Memorial Sloan Kettering Cancer Center

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

MSK has a tentative agreement with Cigna to continue coverage in 2024.

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Romesser sees patients at one location.

Office Phone
Location
New York, NY
1275 York Avenue New York NY 10065

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Collaborators doctors

See all Early Drug Development Service doctors

See all External Beam Radiotherapy Service, Manhattan doctors

See all Brachytherapy Service doctors

Clinical Trials

Research and Publications

View Dr. Romesser's Lab

Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiotherapy and Oncology. 2016; 118(2):286-292. PMID 26867969.

Read more

Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox, JL, Mah D, Garg, MK, Chang J, Lee NY. Proton beam re-irradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. International Journal of Radiation Oncology Biology, and Physics. 2016; 95(1):386-395. PMID: 27084656.

Romesser PB, Romanyshyn JC, Schupak KD, Setton J, Riaz N, Wolden SL, Gelblum DY, Sherman EJ, Kraus D, Lee NY. Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy.  Cancer. 2012; 118(24):6072-6078. PMID 22707358.

Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of Surgical Oncology. 2014; 110(4):375-382. PMID 24961938.

Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, Sherman EJ, Schoder H, Lee NY. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pretreatment 18F-fluorodeoxyglucose positron emission tomography scan. Oral Oncology. 2014; 50(9):802-808. PMID 25043882.

Publications on PubMed

Visit PubMed for a full listing of Dr. Romesser’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Paul Romesser discloses the following relationships and financial interests:

  • EMD Serono, Inc
    Professional Services and Activities
  • Faeth Therapeutics, Inc
    Professional Services and Activities
  • HPV Alliance
    Professional Services and Activities
  • HPV and Anal Cancer Foundation
    Professional Services and Activities (Uncompensated)
  • Natera Inc.
    Professional Services and Activities
  • XRad Therapeutics
    Professional Services and Activities (Uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures